drugset / Trial / NCT00671112
Everolimus and Bortezomib in Treating Patients With Relapsed or Refractory Lymphoma
Phase 1
Terminated
30 enrolled
Brian Hill, MD, PhD
National Cancer Institute (NCI) · collabThe Leukemia and Lymphoma Society · collab
NaSingle-groupOpen-labelTreatment
Summary
RATIONALE: Everolimus and bortezomib may stop the growth of cancer cells by blocking some of the enzymes needed for cell growth. PURPOSE: This phase I trial is studying the side effects and best dose of everolimus when given together with bortezomib in treating patients with relapsed or refractory lymphoma.
Timeline
- Start
- 2008-06
- Primary completion
- 2015-10
- Completion
- —
Outcome
Outcome not reported
Stopped: “Treatment ineffective”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Bortezomib | Small molecule | 0.7 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1 mg/m2 | Intravenous |
| Subject | Bortezomib | Small molecule | 1.3 mg/m2 | Intravenous |
| Subject | Everolimus | Small molecule | 5 mg | Oral |
| Subject | Everolimus | Small molecule | 10 mg | Oral |